1. Global progress in clinical research on human respiratory syncytial virus vaccines.
- Author
-
Ruofan Peng, Chenghao Chen, Qian Chen, Yuwen Zhang, Renjin Huang, Yanjun Zhang, and Jianhua Li
- Subjects
RESPIRATORY syncytial virus ,VIRAL vaccines ,RESPIRATORY diseases ,VACCINE development ,OLDER people - Abstract
Human respiratory syncytial virus (hRSV) not only affects newborns but also older adults, contributing to a substantial worldwide burden of disease. However, only three approved hRSV vaccines remain commercially available to date. The development of a safe, practical and broad-spectrum vaccine suitable for all age groups remains extremely challenging. Using five different approaches—live-attenuated, recombinant-vector, subunit, particle-based, and mRNA—nearly 30 hRSV vaccine candidates are currently conducting clinical trials worldwide; moreover, > 30 vaccines are under preclinical evaluation. This review presents a comprehensive overview of these hRSV vaccines along with prospects for the development of infectious disease vaccines in the post-COVID-19 pandemic era. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF